/biz/ - Business & Finance

>>26784984
>be me
>wake up to phone call from asshole stepdad
>stepdad treated me nice 'till he married in the family, then treated me like shit for no reason for 20 years
>"anon, I can't BELIEVE you are recommending AMC and GME to your friends and family on FakeBook!"
>"what is the FUTURE of EITHER of those companies!?!"
>"I think you're fucking CRAZY!"
>I respond that it's not just a profit making exercise, but a historic lesson in the power of the people that everyone can take part in
>"If everyone buys and holds, we will BANKRUPT several hedge funds"
>tell stepdad to turn on TV and watch pajeet complimenting GME HODLs on sending message to wall street
>tell stepdad we just enabled both companies to sell 1/10th of the stock necessary to pay off COVID losses and still keep their company
>tell stepdad we just bankrupted one hedge fund that exited GME last night with a one BILLION dollar loss!
>stepdad gets pissed off
>stepdad hangs up

>>26571998
BUY THE FUCK OUT OF Vaxart [VXRT] NOW!

https://finance.yahoo.com/news/vaxart-announces-additional-preclinical-covid-133000984.html

They are presenting these results beside Dr. Fauci this week!

>>26454840
[BCRX] - BioCryst Pharmaceutical

Up 16% Friday on news the FDA has approved once-daily Orladeyo as a preventive treatment to prevent hereditary angioedema attacks on patients 12 or older. This makes it the first and only oral treatment to prevent attacks of hereditary angioedema with FDA approval. It has also been approved and will be marketed in Japan, as a part of the same approval. Significant upside next week.

There are rumors it will be bought by Astra Zenica, in which case shares go to $30+.


[CLSN] - Celsion Corporation

This is a cheapie at $1.37 per share, dipping 21% Friday on the announcement of a direct stock offering to a major investment firm, up 57% net over the past 5 trading days. Direct Offering close-out is 1/26, and Institutions buying due to the direct offering Gap will fill shortly, driving up the price.

Based on the high option plays from Friday and the fact that the stock is trading at its Volume Weighted Average Price (VWAP) during after-hours, this company has something big in store next week. Rumors of an announcement of Phase 3 results of a cancer drug that has already shown to increase lifespan of cancer patients by 2 years in Phase 2 studies. Dawson James gave a "Buy" rating with a near-term price target of $4.00.


[AUPH] - Aurinia Pharmaceuticals

Friday announcement late in the day that FDA approved the use of Aurinia Pharmaceuticals’ Lupkynis (voclosporin) as the first oral treatment developed specifically for adults with active lupus nephritis. The market hasn't had a chance to react yet, so expect a pump in before-hours trading Monday.

Based on 6 analysts, average price target is $25.40 with a high forecast of $30.00 and a low forecast of $20.00.

https://www.lupusresearch.org/lupus-research-alliance-hails-approval-of-aurinias-lupkynistm-voclosoporin/

Rumors of a merge abound, with potentially unlimited upside.

https://finance.yahoo.com/news/implied-volatility-surging-aurinia-pharmaceuticals-145602552.html

>>26449316
[CLSN]

Celsion Corp shot up 85.1% toward a six-month high in very active premarket trading, putting the stock on track to more than double in two days after the cancer drug development company disclosed that it terminated a previously announced share purchase agreement with Lincoln Park Capital (LPC).

Celsion has more than doubled over the past three months.This company is planning something BIG for February 2021 or next week based on the high option plays from yesterday. This upcoming week we may have some PR news or at least sometime next month. I have 400 shares at $2.08. Big bounce coming soon.


[CGIX]

Currently trading at $5 up 75% in after-hours trading on strong rumors of buyout by Gilead Sciences at $80 per share to be announced any day.


[CLSN]

Currently trading at $1.25 up 40% in after hours on rumored imminent Phase III Clinical Trial approval announcement, possibly tomorrow.


[ACST]

Acasti Pharma now has 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 3.15 and 1.89 with the average target price sitting at 2.52. With the stocks previous close at 0.63 this is indicating there is a potential upside of 300.0%.

https://firstresearchreports.com/acasti-pharma-acst-509-upside-analysts-predict-the-price-to-be-around-3-35-and-highly-bullish/

https://www.directorstalkinterviews.com/acasti-pharma---consensus-indicates-potential-300.0-upside/412954122


[ONTX]

Up from 0.35 to 0.75 per share in 30 days on sufficient funding into 2022, pending announcements of positive results from pending drugs coming as soon as days or weeks. Look for a huge permanent spike tomorrrow. This will climb well over $10 a share in 4 days to 4 months.

PPT Presentation: https://investor.onconova.com/static-files/5fe03f21-cc14-4820-a7a3-20e888a62b2c